BOSTON, April 23, 2020 – In September, Jonathan D. Campbell, PhD, will become Senior Vice President for Health Economics at the Institute for Clinical and Economic Review (ICER). Having collaborated with ICER closely over the past five years, Dr. Campbell will oversee the growth of ICER’s health economics team and lead in the future innovation of ICER’s value assessment methodology. In addition, he will continue to build ICER’s relationships with health economists around the country and with health technology assessment (HTA) agencies around the world.

“Jon is a world-class researcher and team builder,” noted Steven D. Pearson, MD, MSc, President of ICER. “He’s known for his scientific rigor and innovative research on theoretical methods, but just as importantly, he’s known for applying economic models in very personal and practical ways, never losing sight of the patient experience. He is a generous colleague, a knowledgeable mentor for his teams, and relentless in following wherever the evidence leads.”

Over the next few months, Dr. Campbell will be transitioning out of his current position as an Associate Professor at University of Colorado’s Anschutz Medical Campus, where he is also Director of the Center for Pharmaceutical Outcomes Research (CePOR). He is the author of more than 100 peer-reviewed manuscripts on the topics of value assessment research applications, methods, and measurement. Dr. Campbell received a PhD in pharmaceutical outcomes research and policy, as well as a MS in biostatistics, from the University of Washington. He earned bachelor’s degrees in mathematics and chemistry at St. Olaf College, where he graduated magna cum laude, Phi Beta Kappa.

“As an external collaborator, I’ve had a back-stage pass to encourage ICER’s growth from a high-minded academic project to a prominent research organization that’s now driving the national conversation around fair pricing and fair access,” said Dr. Campbell. “Tenured faculty don’t typically leave academia, but ICER represents a matchlessly high-impact opportunity for me to combine my research experience and my passion to help all Americans access the medicines they need today and in the future at fair prices. ICER’s process for evidence synthesis and generation uniquely bridges and engages patients and other key stakeholder groups in US value assessment. I am joining a passionate and growing team that advances challenging yet worthy goals to improve US health care. For my family, there was a high bar to move us away from our Denver community. ICER far exceeds this bar.”

ICER continues to expand its team. For a full listing of open positions – including Director of Health Economics, Research Lead, Deputy Chief Scientific Officer, and Deputy Chief Medical Officer – please visit ICER’s website.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.